Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Surachat Ngorsuraches & Nabin Poudel. (2021) Incorporating patients’ preferences in the value assessment of disease-modifying therapies for multiple sclerosis: a narrative review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 183-195.
Read now
Read now
Hongbo Yang, Emilie Duchesneau, Rebekah Foster, Annie Guerin, Esprit Ma & Nina P. Thomas. (2017) Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis. Journal of Medical Economics 20:10, pages 1056-1065.
Read now
Read now
Olivier Outteryck. (2016) Natalizumab in relapsing-remitting multiple sclerosis. Expert Review of Neurotherapeutics 16:5, pages 471-481.
Read now
Read now
Daniel Resende Faleiros, Juliana Álvares, Alessandra Maciel Almeida, Vânia Eloisa de Araújo, Eli Iola Gurgel Andrade, Brian B. Godman, Francisco A. Acurcio & Augusto A. Guerra Júnior. (2016) Budget impact analysis of medicines: updated systematic review and implications. Expert Review of Pharmacoeconomics & Outcomes Research 16:2, pages 257-266.
Read now
Read now
Emily Dorman, Anuraag R. Kansal & Sujata Sarda. (2015) The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada. Journal of Medical Economics 18:12, pages 1085-1091.
Read now
Read now
Ken O’Day, Kellie Meyer, Dana Stafkey-Mailey & Crystal Watson. (2015) Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. Journal of Medical Economics 18:4, pages 295-302.
Read now
Read now
Machaon M Bonafede, Barbara H Johnson & Crystal Watson. (2014) Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. ClinicoEconomics and Outcomes Research 6, pages 11-20.
Read now
Read now
Leonardo Koeser & Paul McCrone. (2013) Cost–effectiveness of natalizumab in multiple sclerosis: an updated systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 13:2, pages 171-182.
Read now
Read now
Ken O’Day, Kellie Meyer, Ross M. Miller, Sonalee Agarwal & Meg Franklin. (2011) Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. Journal of Medical Economics 14:5, pages 617-627.
Read now
Read now
Articles from other publishers (17)
Anggie Wiyani, Lohit Badgujar, Vivek Khurana & Nicholas Adlard. (2021) How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review. Neurology and Therapy 10:2, pages 557-583.
Crossref
Crossref
Anna Mokrova, Susanna Sologova & Victoria Ignatyeva. (2020) Modelling expenses for multiple sclerosis treatment. Farmacevticheskoe delo i tehnologija lekarstv (Pharmacy and Pharmaceutical Technology):3, pages 11-34.
Crossref
Crossref
B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore & C Gasperini. (2019)
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri
®
PharmacoEconomics (TyPE) Study
. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 2019, pages 228424031985295.
Crossref
Crossref
Afsaneh Shirani & Olaf Stüve. (2018) Natalizumab: Perspectives from the Bench to Bedside. Cold Spring Harbor Perspectives in Medicine 8:12, pages a029066.
Crossref
Crossref
Pratyusha VadagamKhalid M. KamalJordan R. CovveyVincent GiannettiKumar Mukherjee. (2018) Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis. Journal of Managed Care & Specialty Pharmacy 24:10, pages 987-997.
Crossref
Crossref
Sergio Iannazzo, Ange-Christelle Iliza & Louise Perrault. (2017) Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies. PharmacoEconomics 36:2, pages 189-204.
Crossref
Crossref
Ankur A. DashputreKhalid M. KamalGauri Pawar. (2017) Cost-Effectiveness of Peginterferon Beta-1a and Alemtuzumab in Relapsing-Remitting Multiple Sclerosis. Journal of Managed Care & Specialty Pharmacy 23:6, pages 666-676.
Crossref
Crossref
Josephine Mauskopf & Stephanie Earnshaw. (2016) A Methodological Review of US Budget-Impact Models for New Drugs. PharmacoEconomics 34:11, pages 1111-1131.
Crossref
Crossref
Damiano Paolicelli, Sergio Iannazzo, Laura Santoni, Antonio Iaffaldano, Valentina Di Lecce, Alessia Manni, Vito Lavolpe, Carla Tortorella, Mariangela D'Onghia, Vita Direnzo, Elisa Puma & Maria Trojano. (2016) The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy. PLOS ONE 11:7, pages e0159214.
Crossref
Crossref
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca & X. Montalbán. (2015) Spanish consensus on the use of natalizumab (Tysabri®)-2013. Neurología (English Edition) 30:5, pages 302-314.
Crossref
Crossref
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca & X. Montalbán. (2015) Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013. Neurología 30:5, pages 302-314.
Crossref
Crossref
Shien Guo, Christopher Pelligra, Catherine Saint-Laurent Thibault, Luis Hernandez & Anuraag Kansal. (2014) Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches. PharmacoEconomics 32:6, pages 559-572.
Crossref
Crossref
Sean D. Sullivan, Josephine A. Mauskopf, Federico Augustovski, J. Jaime Caro, Karen M. Lee, Mark Minchin, Ewa Orlewska, Pete Penna, Jose-Manuel Rodriguez Barrios & Wen-Yi Shau. (2014) Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value in Health 17:1, pages 5-14.
Crossref
Crossref
Annie Hawton, James Shearer, Elizabeth Goodwin & Colin Green. (2013) Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis. Applied Health Economics and Health Policy 11:4, pages 331-341.
Crossref
Crossref
Joel P. Thompson, Amir Abdolahi & Katia Noyes. (2013) Modelling the Cost Effectiveness of Disease-Modifying Treatments for Multiple Sclerosis. PharmacoEconomics 31:6, pages 455-469.
Crossref
Crossref
João Sargento-Freitas, Sonia Batista, Carmo Macario, Fernando Matias & Livia Sousa. (2013) Clinical predictors of an optimal response to natalizumab in multiple sclerosis. Journal of Clinical Neuroscience 20:5, pages 659-662.
Crossref
Crossref
David Yamamoto & Jonathan D. Campbell. (2012) Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature. Autoimmune Diseases 2012, pages 1-13.
Crossref
Crossref